Fredun Pharmaceuticals has informed that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026, to consider and approve Audited Financial Results & Statements (Standalone & Consolidated) for the fourth quarter and financial year ended 31st March, 2026; consider and recommend final dividend on the paid-up equity shares for the Financial Year ended 31st March, 2026; and consider and recommend Bonus Equity Shares subject to approval of Members of the Company.
The above information is a part of company’s filings submitted to BSE.
